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Abstract
Background—Despite medical advances, children with dilated cardiomyopathy (DCM) remain
at high risk of death or need for cardiac transplantation. We sought to identify predictors of
disease progression in pediatric DCM.
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Methods and Results—The Pediatric Heart Network evaluated chronic DCM patients with
prospective echocardiographic and clinical data collection during an 18-month follow-up.
Inclusion criteria were age <22 years and DCM disease duration >2 months. Patients requiring
intravenous inotropic/mechanical support or listed status 1A/1B for transplant were excluded.
Disease progression was defined as an increase in transplant listing status, hospitalization for heart
failure, intravenous inotropes, mechanical support, or death. Predictors of disease progression
were identified using Cox proportional hazards modeling and classification and regression tree
analysis. Of the 127 patients, 28 (22%) had disease progression during the 18-month follow-up.
Multivariable analysis identified older age at diagnosis (hazard ratio=1.14 per year; P<0.001),
larger left ventricular (LV) end-diastolic M-mode dimension z-score (hazard ratio=1.49; P<0.001),
and lower septal peak systolic tissue Doppler velocity z-score (hazard ratio=0.81; P=0.01) as
independent predictors of disease progression. Classification and regression tree analysis stratified
patients at risk of disease progression with 89% sensitivity and 94% specificity based on LV enddiastolic M-mode dimension z-score ≥7.7, LV ejection fraction <39%, LV inflow propagation
velocity (color M-mode) z-score <-0.28, and age at diagnosis ≥8.5 months.
Conclusions—In children with chronic stable DCM, a combination of diagnosis after late
infancy and echocardiographic parameters of larger LV size and systolic and diastolic function
predicted disease progression.
Keywords
cardiomyopathies; heart transplantation; pediatrics

NIH-PA Author Manuscript

Dilated cardiomyopathy (DCM) is the most common pediatric cardiomyopathy, an
important cause of heart failure (HF) and a leading cause of heart transplantation in
children.1–4 Despite recent medical advances, event-free survival remains poor, with 5-year
rates of death or transplantation reported as high as 46%.1 A limited number of risk factors
have been consistently identified to help predict outcomes; older age at presentation and
decreased indices of systolic left ventricular (LV) function have been associated with a
worse prognosis in multiple studies.5–13 However, the sensitivity of these parameters in
early risk stratification and prediction of adverse events remains limited. Newer
echocardiographic modalities have shown promise in identifying abnormalities that may be
associated with adverse events, such as comprehensive assessment of ventricular
dysfunction with tissue Doppler imaging (TDI); however, these modalities have not yet been
studied in a comprehensive manner in a large prospective cohort of pediatric patients with
DCM.14–17 Early risk stratification would help guide frequency of monitoring and optimize
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timing and type of interventions, including medications or device therapies and, ultimately,
cardiac transplantation. The purpose of this study was, therefore, to identify clinical and
echocardiographic factors associated with disease progression in children with DCM.

Methods
The study was part of the Ventricular Volume Variability (VVV) Study conducted through
the Pediatric Heart Network, a multicenter clinical research consortium. The VVV study is a
multicenter, observational study of a prospectively enrolled cohort of children with DCM.
Subjects were enrolled at 8 study centers between May 2005 and July 2007. The study was
approved by an institutional review board at all sites with informed consent obtained from
all subjects. The core laboratory measurements from echocardiograms performed at study
enrollment were used in the analysis. Demographic information and clinical data were
obtained during regularly scheduled visits throughout the 18-month follow-up period. The
primary aim of this report was to identify echocardiographic and clinical variables present at
the time of enrollment that correlated with subsequent disease progression.
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Significant disease progression was defined as any of the following: hospitalization for HF,
initiation of intravenous inotropic support, transplant listing or increase in listing status,
decompensated HF requiring mechanical circulatory support, or death. Patient enrollment
criteria included age <22 years, diagnosis of DCM based on the first study echocardiogram
with an LV end-diastolic dimension (EDD) >5.5 cm (or z-score for age >2) and LV ejection
fraction (EF) <50% or shortening fraction <28% (or z-score for age <-2), disease duration
>2 months, anticipated ongoing evaluation at the same institution, and informed consent.
Exclusion criteria included other forms of cardiomyopathy including noncompaction,
congenital heart disease, frequent ectopy, need for intravenous or mechanical hemodynamic
support, and transplant listing status of 1A or 1B at the time of screening. Only 2 patients
without an event, of the 127 total, had <18 months of follow-up because of early withdrawal
from the study. Patient data collected included age, sex, height, weight, blood pressure, race,
cause of DCM, and medication type and dose. Body surface area was calculated using the
Haycock formula.18
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All centers followed a standardized protocol for echocardiographic image acquisition.
Baseline transthoracic echocardiograms performed at study enrollment were submitted to
the core laboratory for measurement of echocardiographic variables (M-mode, 2dimensional, Doppler, and TDI) by 2 experienced readers. For each variable, measurements
were performed on 3 sequential cardiac cycles. Thirty-five parameters of LV dimension,
mass, and systolic and diastolic function obtained from the enrollment echocardiograms and
28 clinical factors were included for analysis as predictors of disease progression (please
refer to the Table in the online-only Data Supplement for detailed list). A previous VVV
analysis on the effect of beat averaging on reproducibility of echocardiographic variables
showed that use of 3-beat averaging reduced inter- and intrareader variability, and thus the
3-beat average measurements using the primary core reader's interpretation were used in this
analysis.19 All echocardiographic measurements were made using custom DICOM software
(EchoTrace, Marcus Laboratories, Boston, MA) according to previously published
techniques.19 Z-scores on echocardiographic measurements (for body surface area or age)
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were used where applicable. LV flow propagation z-scores were calculated using the
following formula: z-score=(LV flow propagation– 0.191×age+66.7)/(24.5–0.132×age).
Additional data points were assessed as both percentages and z-scores, including shortening
fraction and EF. Further analysis of mitral regurgitation was undertaken; vena contracta
width (VCW) was calculated as the average of the dimensions from orthogonal planes
(parasternal long-axis and apical 4-chamber views). Mitral regurgitation grade was
evaluated subjectively based on visual appearance and objectively based on VCW adjusted
to body surface area as adjusted VCW (mm/m)=VCW/body surface area0.5.20 Severity
categories were defined as mild, moderate, and severe for adjusted VCW <3, 3 to 4.5, and
>4.5, respectively. Patients with adjusted VCW within 0.3 mm/m of a boundary value were
adjudicated based on visual estimate of severity.
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Univariate predictors of time to disease progression were identified using Cox proportional
hazards regression. Multivariable modeling used a stepwise Cox proportional hazards
procedure for all variables with a univariate P<0.2. A P<0.1 was then required to remain in
the model and determine independent predictors. Certain candidate predictors were not
included in the multivariate analysis as a result of excessive missing data (see starred items
in the online-only Data Supplement), including Doppler variables that were only measurable
in the absence of a mitral valve inflow summation wave. Logistic regression analysis was
also performed, with identical significant findings demonstrating that use of a dichotomous
outcome measure for this analysis is robust to small differences in length of follow-up. As
such, a classification and regression tree (CART) analysis was performed to construct a risk
stratification algorithm to predict disease progression.21 CART is a nonparametric technique
that produces a decision tree by a series of binary splits (recursive partitioning) of the data.
The CART model selects variables in order of magnitude of improvement in prediction of
the outcome, and the variables that contribute the most to the outcome are listed first at the
top of the tree. Analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary,
NC) and an open-source adaptation of the CART algorithm (RPART library in R version
2.14.1).

Results
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Of the 127 patients in the analytic cohort, median age at enrollment was 9.2 years
(interquartile range, 4.0–15.0 years). Table 1 summarizes the demographic information of
patients who subsequently developed disease progression compared with those who did not.
At the time of enrollment, most patients were classified as having New York Heart
Association/Ross class I or II HF symptoms. Medical therapy included angiotensinconverting enzyme inhibition (83%), digoxin (59%), diuretics (54%), and β-blockers (53%).
Of the 28 patients (22%) who met criteria for disease progression, 3 died, 16 were
transplanted, 3 required initiation of intravenous inotropes, 1 received an LV assist device, 7
had an increase in listing status, and 14 were hospitalized for worsened HF (not mutually
exclusive). The majority of patients with disease progression had a diagnosis of idiopathic
DCM (n=20), followed by Adriamycin-associated cardiotoxicity (n=3); no patients with
myocarditis subsequently developed disease progression in this follow-up period. Figure 1
depicts the freedom from disease progression for the entire cohort; 6- and 12-month rates of
disease progression were 15% and 22%, respectively. Table 2 outlines the univariate
Circ Heart Fail. Author manuscript; available in PMC 2014 July 25.
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associations between baseline clinical and echocardiographic variables in patients with
disease progression with a P<0.2 (for a comprehensive listing of all predictors assessed,
refer to the Table in the online-only Data Supplement). Clinical factors associated with
disease progression on univariate analysis included older age at diagnosis, more recent
diagnosis of DCM, male sex, and symptomatic HF—specifically increased symptoms of
exercise intolerance, feeding difficulties, dyspnea, need for hospitalization, and intravenous
inotropes in the 6 months before enrollment. Echocardiographic indices associated with
disease progression included measures of LV size, degree of mitral regurgitation, as well as
dimensional and volumetric assessments of systolic function. Diastolic assessments using
mitral inflow measurements and TDI were also significantly associated with disease
progression; however, many of these parameters were not included in subsequent
multivariate analysis as a result of incomplete separation of early and late diastolic flows or
annular motion (Doppler summation waves) resulting in missing data (see asterisked
variables in the online-only Data Supplement).
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Independent predictors of disease progression on multivariate analysis included older age at
diagnosis (P<0.001), larger M-mode LV EDD z-score (P<0.001), and lower septal peak
systolic TDI velocity z-score at enrollment (P=0.01; Figure 2). Older age at diagnosis was
associated with disease progression with a hazard ratio (HR) of 1.14 per 1 year increase in
age at enrollment (confidence interval, 1.06–1.23). Echocardiographic evidence of larger LV
EDD at enrollment was the strongest predictor of disease progression with an HR of 1.49 for
every unit z-score increase (confidence interval, 1.32–1.69). In addition, a higher septal peak
systolic TDI velocity z-score was protective against disease progression with an HR of 0.81
for every unit z-score increase (confidence interval, 0.69–0.95).
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Given the relatively large number of associated variables on Cox proportional hazards
modeling, a CART analysis was performed to identify the variables with the highest
discriminatory power to predict disease progression. This analysis identified a combination
of 3 echocardiographic and 1 clinical factor to be useful in risk stratifying these patients
(Figure 3). M-mode LV EDD z-score was identified as the top discriminator of disease
progression, with 14 of 15 (93%) patients with LV EDD z-score >7.7 showing disease
progression compared with 13% of patients with LV EDD z-score <7.7. In patients with LV
EDD z-score <7.7, LV EF emerged as a predictor of disease progression, with 12 of 36
(33%) patients with LV EF <38% showing disease progression compared with only 3% of
those with a higher EF. LV flow propagation velocity z-score served as a further
discriminator; among those with an LV EDD z-score <7.7 and LV EF <38%, 12 of 24 (50%)
patients with an LV flow propagation velocity z-score <-0.28 had disease progression
compared with none of the 12 patients with a z-score >-0.28. The final discriminator was age
at diagnosis. In children with an LV EDD z-score <7.7, an LV EF <38%, and an LV flow
propagation z-score <-0.28, 11 of 16 (69%) patients >8.5 months at diagnosis had disease
progression compared with 1 of 8 (12%) patients <8.5 months at diagnosis. This risk
algorithm tree had a sensitivity of 89%, a specificity of 94%, and a predictive accuracy of
93% for identifying patients who experienced disease progression (Table 3). Figure 4
depicts the Kaplan–Meier curve comparing those individuals identified by CART analysis to
be at high risk of disease progression with those at low risk of progression.
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Transplant-free survival in children with DCM has not appreciably improved in recent
decades.11–13 In adults with HF, models have been devised to accurately assess patient risk
of mortality largely based on prognostic factors incorporating patient demographics (age,
sex), clinical parameters of HF (New York Heart Association class, EF, blood pressure,
maximal oxygen consumption [Vo2]), medical therapies used (drug dosing, devices), and
serum biomarkers of disease severity (hemoglobin, lymphocyte counts, sodium levels, total
cholesterol, and uric acid).22,23 Robust predictors of disease progression in pediatric DCM
are lacking. Our study assessed many of the above parameters, with the exception of
laboratory markers and Vo2, in an attempt to identify prognostic factors for pediatric DCM
disease progression in chronically stable outpatients. This analysis confirms the importance
of age at diagnosis and echocardiographic evidence of LV size and impaired systolic and
diastolic function as predictors of disease progression and associated adverse events. Unlike
most published studies that have used a retrospective or registry design, our prospective
study has unique strengths and allowed for the development of a model predictive of disease
progression with high sensitivity, specificity, and predictive accuracy. If validated in
additional populations, this model may provide a clinically useful decision making tool.
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Patients who showed disease progression were more symptomatic and had more severe
echocardiographic abnormalities at enrollment. However, older age at diagnosis in this study
was the only clinical parameter that remained independently associated with disease
progression on multivariate analysis. Patient age has long been identified as an important
predictor of outcome in both children and adults with DCM, with older school-aged children
at increased risk in pediatric DCM studies.1–3,5,9,11–13 In addition, there is some evidence
that infants may also be at risk. Tsirka et al11 identified 2 age groups at risk for death/
transplantation: those aged <1 year at diagnosis (HR, 7.1) and an older subset aged >12
years (HR, 4.5).
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A pediatric cohort from Australia also pointed to a possible bimodal distribution of agerelated risk, with a trend toward worse survival in children aged <1 year.2 The younger
subset of patients in our study cohort was not identified to be at increased risk, but the
inclusion criteria requiring a minimum of 2-month duration with the diagnosis of DCM and
the relatively small patient sample in this age range may have limited our ability to
extrapolate the effect of a diagnosis of DCM in early infancy on long-term prognosis.
Interestingly, no other demographic parameters or clinical symptoms were independently
predictive of worse outcome in this analysis; this contrasts with the recent study by Alvarez
et al13 that used the Pediatric Cardiomyopathy Registry of patients with idiopathic DCM in
which the severity of HF symptoms at diagnosis was the single strongest predictor of death
or transplantation. This difference could be because of the focus in the VVV study on a
cohort of chronic stable DCM outpatients, thus excluding those patients with symptomatic
HF requiring inotropic support at the time of enrollment. The emergence of
echocardiographic parameters as independent predictors of progression suggests that
echocardiography provides a more objective assessment of disease severity compared with
clinical symptomatology.
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Echocardiography plays a prominent role in both diagnosis and ongoing evaluation of
patients with DCM. This analysis highlights the immense value that standard imaging
techniques can add in identifying patients at risk for a poor outcome. The prospective nature
of this study allowed for a standardized and comprehensive assessment of a relatively larger
number of echocardiographic variables than has previously been studied in children. Our
study confirmed previously identified associations of larger LV dimensions, decreased
indices of LV systolic and diastolic function, as well as degree of mitral regurgitation as
important univariate predictors of disease progression.5–14,24,25 On multivariate analysis, the
strongest predictor of disease progression was larger LV EDD, with further evidence of its
importance found in the CART analysis algorithm. Increasing LV EDD is a part of the
cardiac remodeling process in patients with decreased systolic function and DCM. Larger
LV EDD has long been found to correlate with adverse clinical outcome1,2,11,13,25,26 and
has been associated with increased mortality in patients with DCM listed for cardiac
transplantation, particularly the infant subset, as well as affecting survival in the first 6
months after transplant.25 The Pediatric Cardiomyopathy Registry found that a larger LV
EDD was associated with increased risk of transplantation but a decreased risk of death.13
This finding may be because of an aspect of referral bias, where children with larger LV
EDD may be directed toward transplantation earlier, potentially limiting true assessment of
their overall mortality risk. Regardless, the use of LV EDD has repeatedly been identified as
a powerful prognosticating tool in pediatric DCM.
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Our study also found that lower peak septal systolic velocity z-scores by TDI were
associated with worse clinical outcome on multivariate analysis. This TDI parameter
highlights both the role of diminished systolic function in these patients and may further
signify the importance of biventricular structural interdependence and functional
augmentation that can be lost as a consequence of DCM. As one of the newer imaging
modalities, TDI has proven useful in evaluating both systolic and diastolic function in
several disease processes and now has become a standard part of echocardiographic
assessment. McMahon et al14 found that TDI velocities were significantly reduced in
children with DCM compared with normal controls and that tricuspid velocity during early
diastole was a predictor of patients who subsequently died or needed transplantation. In
adult patients with chronic systolic HF, septal TDI measurements were found to be more
reliable and clinically relevant compared with lateral TDI measurements, with higher septal
E/Ea ratios being correlated with natriuretic peptide levels and adverse cardiac events.27 In
adults with HF, septal TDI has also been shown to be of value in identifying patients who
may benefit from cardiac resynchronization therapy.28
CART modeling and analysis identified a combination of LV dimension, LV systolic and
diastolic function, and the clinical parameter of age at diagnosis as valuable in risk
stratifying this cohort of patients with high sensitivity, specificity, and predictive accuracy.
Although each of the 4 parameters shows some discriminating value, it is the combination of
all 4 components that yields the best prognostic value (Table 3). LV dimension, specifically
an LV EDD z-score ≥7.7, remained as the top predictor on CART analysis. The degree of
LV systolic dysfunction added an additional important determinant of prognosis, with an LV
EF <38% demonstrating incremental value in further subcategorizing patients with a less
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dilated phenotype (LV EDD <7.7 z-score) of DCM. Measures of decreased systolic function
at presentation, both by shortening fraction and by EF, previously have been associated with
worse prognosis in patients with DCM.1,2,11,12,25,29 Kantor et al12 determined that patients
with a lower EF at presentation exhibited a substantially increased risk of death or
transplantation, with an incremental increased risk of 35% for every 10% decrease in LV EF
at presentation. Furthermore, patients who show no significant improvement in LV function
after initiation of medical therapy are at increased risk, with persistently decreased
shortening fraction <20% in long-term follow-up strongly associated with poor outcome in
the pediatric DCM population.2
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The final echocardiographic component in the CART algorithm used the diastolic
assessment of LV flow propagation to characterize patients at risk for disease progression.
This measurement of the slope of the color Doppler mitral inflow wave during early LV
filling has been used as a non-invasive assessment of LV relaxation. Although this
calculation is not regularly performed as a part of the standard pediatric echocardiogram, it
has proven useful in evaluating patients with abnormal LV relaxation, including different
forms of cardiomyopathy and systemic hypertension. Brun et al30 found that the velocity of
flow propagation was lower in patients with DCM and proved a useful tool in studying
diastolic function. Although LV flow propagation was not identified as an independent
predictor of disease progression in this patient population, it provides additional stratifying
power if the z-score is <-0.28 for determining patients at risk for worse outcomes when used
in conjunction with LV EDD and EF. Prospective collection of an extensive list of
echocardiographic parameters of cardiac size and function with concurrent clinical factors
allowed for the CART analysis and formulation of a well-designed risk stratification tool
that, once further validated in other patient groups, may help practitioners enhance their
ability to prognosticate disease progression in their patients.

Study Limitations
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The purpose of this study was to evaluate patients with chronic, stable DCM that resulted in
exclusion of those who at the time of enrollment manifested rapidly advancing or end-stage
HF. Thus, the results of this study may not be generalizable to patients acutely presenting
with DCM or those requiring intravenous inotropic or mechanical support early in their
clinical course. Furthermore, the robustness of these predictors is limited by the small
sample size. The follow-up period to determine disease progression was relatively short
compared with other studies,1,2 and longer evaluation might prove useful to better
understand the large number of factors affecting the natural history of pediatric DCM. As a
result of limited numbers of patients with additional laboratory markers, such as natriuretic
peptides or exercise testing Vo2 measurements, the influence of these markers of HF could
not be assessed in our study. Independent validation of our CART risk algorithm in other
populations of patients with pediatric DCM is needed to confirm its use as a risk-stratifying
tool.
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Conclusions
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In children with chronic stable DCM, diagnosis after late infancy and echocardiographic
parameters of LV size and systolic and diastolic dysfunction were independently associated
with disease progression. If confirmed in other populations, the proposed CART algorithm
may be useful to reliably risk stratify patients with DCM and identify those who might
benefit from more frequent monitoring, intensification of medical treatment, or earlier
consideration of mechanical support and transplant evaluation and listing.
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Predictors of disease progression in children with clinically stable heart failure are
lacking. Early risk stratification may help guide frequency of monitoring and help
optimize timing of medical and device therapy and of cardiac transplantation. In this
prospective study, we identified clinical and echocardiographic factors including age at
diagnosis, left ventricular M-mode dimension z-score, and septal systolic tissue Doppler
imaging velocity z-score as being associated with disease progression in 127 pediatric
patients with chronic stable dilated cardiomyopathy. A model was developed with high
sensitivity and specificity in identifying patients at risk of disease progression. This
model requires further validation in additional cohorts for application as a clinical
algorithm for risk stratification of pediatric patients with chronic stable dilated
cardiomyopathy.
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Figure 1.

Kaplan–Meier curve demonstrating percentages of patient cohort meeting criteria for
clinically significant disease progression during the 18-month time interval. Within 9.8
months after enrollment, 20% of the population developed significant disease progression.
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Figure 2.

Box plots demonstrating the 3 independent predictors of disease progression: (A) age at
diagnosis, (B) left ventricular end-diastolic dimension (LV EDD) z-score, and (C) septal
tissue Doppler imaging (TDI) systolic velocity z-score.
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Figure 3.

Classification and regression tree analysis risk stratifying patients with significant disease
progression by 3 echocardiographic and 1 clinical factor. EDDz indicates left ventricular
end-diastolic dimension z-score; EF, ejection fraction; and LV flow prop., left ventricular
propagation velocity slope.
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Figure 4.

Kaplan–Meier curve demonstrating patients at high risk of disease progression versus low
risk. Definition of risk was based on whether patients met criteria on the classification and
regression tree analysis for significant disease progression using all 4 tiers
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Table 1

Demographics by Disease Progression
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Stable Disease

Progressive Disease

99

28

n
Male

P Value*

39 (39%)

17 (61%)

0.054

Age at diagnosis, y

1.1 (0.3–10.2)

7.5 (0.9–13.5)

0.04

Age at enrollment, y

8.8 (4.0–15.0)

9.4 (3.6 –14.8)

0.869

Time from diagnosis of cardiomyopathy to enrollment, y

3.5 (0.6–6.8)

0.8 (0.3–3.0)

0.006

Length of follow-up, y

1.5 (1.1,1.5)

0.5 (0.2,1.3)

<0.001
0.002 <0.001†

Ross/NYHA Heart Failure Classification
Class I

73 (74%)

11 (39%)

Class II

23 (23%)

14 (50%)

Class III

3 (3%)

3 (11%)

Class IV

0 (0%)

0 (0%)

Primary cause of dilated cardiomyopathy

0.329

NIH-PA Author Manuscript

Metabolic disorder

2 (2%)

0 (0%)

Mitochondrial disorder

1 (1%)

1 (4%)

Neuromuscular disease associated with cardiomyopathy

2 (2%)

2 (7%)

Single gene defect

3 (3%)

1 (4%)

Adriamycin-associated cardiotoxicity

11 (11%)

3 (11%)

Idiopathic

65 (66%)

20 (71%)

Myocarditis

6 (6%)

0 (0%)

Other

9 (9%)

1 (4%)

Median (IQR) or frequency (%) is shown. IQR indicates interquartile range; and NYHA, New York Heart Association.
*

Wilcoxon rank-sum test for medians or a Fisher exact test for frequencies.

†

Mantel–Haenszel test for trend.
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28
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99
98
99
99

LV mass z-score, M-mode

LV mass z-score, 2D

Mass to volume ratio z-score

Sphericity index z-score

98
99

Posterior wall thickness to dimension ratio, M-mode z-score

99

Posterior wall thickness to dimension ratio, 2D z-score

99

End-diastolic short-axis dimension, M-mode z-score

1.0±1.3

−1.0±1.1

1.9±1.7

1.3±1.5

−1.5±1.2

−1.8±1.0

3.6±2.4

3.4±1.8

53 (55%)
19 (20%)

−1 ≤Z≤1

Z>1

End-diastolic short-axis dimension, 2D z-score

25 (26%)

97

Weight-for-age z-score

8 (9%)

9 (10%)

32 (32%)

11 (11%)

Z<-1

91
90

Intravenous inotropic medications in 6 mo before enrollment

99

Feeding difficulties or exercise intolerance in 6 mo before enrollment

Palpitations in 6 mo before enrollment

99

Dyspnea in 6 mo before enrollment

28

28

27

26

28

27

27

26

28

27

24

28

27

28

2.0±1.4

−1.7±1.2

4.6±2.3

3.2±2.2

−2.2±1.3

−2.6±1.0

7.8±4.3

7.4±3.7

7 (25%)

10 (36%)

11 (39%)

7 (26%)

5 (21%)

18 (64%)

12 (44%)

6 (21%)

5 (18%)

98

Failure to thrive in 6 mo before enrollment

9 (9%)

2 (2%)

17 (61%)

15 (54%)

6 (21%)

28

11 (11%)

No. of hospitalizations related to heart failure
86 (87%)

26 (26%)

99
99

Hospitalized in previous 6 mo

14 (50%)

14 (50%)

17 (61%)

0.79 (0.27–2.97)

7.5 (0.9–13.5)

Progressive Disease
(n=28)

1

30 (30%)

28

28

28

28

n

0

69 (70%)

White

39 (39%)

Other or unknown race

99
99

Male

Race

3.47 (0.56–6.84)

1.1 (0.3–10.2)

99
99

Median age at diagnosis of cardiomyopathy, y (IQR)

Stable Disease
(n=99)

n

Median time from diagnosis to baseline echo, y (IQR)

Variable*

2

NIH-PA Author Manuscript
<0.001

0.003

<0.001

<0.001

0.004

<0.001

<0.001

<0.001

0.18

0.01

0.15

0.02

<0.001

0.08

<0.001

0.007

0.06

0.04

0.01

0.03

P Value†

Univariate Predictors of Significant Disease Progression With P<0.2 Using Cox Proportional Hazards Process
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Median (IQR)

Median mitral regurgitation jet
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98
94

Septal AV valve peak systolic velocity z-score

Right lateral AV valve peak systolic velocity z-score

Left ventricular flow propagation velocity z-score

−0.3±0.9

−0.2±1.4

−1.4±2.1

0.42±0.16

28

28

26

27

−0.7±0.5

−1.1±1.4

−3.1±2.2

0.54±0.25

−2.3±1.2

16 (57%)
26

21 (21%)
−1.2±1.4

12 (43%)

8 (29%)

8 (29%)

9 (32%)

3 (11%)

0.3 (0.2–0.5)

−7.5±2.4

27.1 (19.1–35.0)

27.9±11.4

241.4±33.1

−7.2±1.8

11.7 (8.3–13.2)

11.6±5.3

−12.1±4.8

12.0 (8.7–16.7)

12.8±4.8

0.92 (0.90–0.93)

Progressive Disease
(n=28)

77 (79%)

28

28

28

28

28

28

28

28

28

28

27

27

27

28

n

0.02

<0.001

<0.001

0.001

<0.001

<0.001

0.003

<0.001

<0.001

<0.001

0.003

<0.001

<0.001

<0.001

<0.001

0.001

P Value†

P value is from Cox proportional hazards comparing stable disease with significant disease progression.

All measures are from the time of study enrollment unless otherwise noted.

†

*

All echocardiographic measures are from the left ventricle, where applicable. 2D indicates 2-dimensional; AV, atrioventricular; IQR, interquartile range; and LV, left ventricular.

99
99

Tei index

99

Left lateral AV valve peak systolic velocity z-score

Moderate/severe

None/mild

Severity of mitral valve regurgitation

98

13 (13%)

Moderate
8 (8%)

44 (45%)

Severe

33 (34%)

Mild

98

0.2 (0.0–0.3)

−4.3±2.1

44.0 (37.6–51.0)

43.1±9.7

263.6±36.3

−5.1±1.9

18.6 (14.3–23.7)

18.7±6.2

−6.1±3.9

None

Severity of mitral valve regurgitation

98

99

Ejection fraction, %

width/BSA0.5

99
99

Aortic ejection time, M-mode, ms

Ejection fraction z-score

99
99

Shortening fraction, 2D z-score

99

99

Median IQR

Shortening fraction, 2D %

(IQR)

21.9 (18.0–27.0)

99
99

Shortening fraction, M-mode z-score

Median IQR

21.7±6.4

0.93 (0.92–0.94)

99
99

Median eccentricity index (IQR)
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Shortening fraction, M-mode, %

Stable Disease
(n=99)
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86.9%
93.9%

80.6%

66.7%

51.0%

93.3%

PPV

96.9%

97.7%

97.4%

87.5%

NPV

92.9%

88.2%

78.7%

88.2%

Accuracy

CART indicates classification and regression tree; EDDz, left ventricular end-diastolic dimension z-score; EF, ejection fraction; LV, left ventricular; NPV, negative predictive value; PPV, positive
predictive value; and prop., propagation velocity slope.

92.9%
89.3%

EDDz ≥7.7, EF <38.2, and LV flow prop. z <-0.281

All 4 variables

74.7%

99.0%

50.0%
92.9%

EDDz ≥7.7 only

Specificity

Sensitivity

EDDz ≥7.7 and EF <38.2

Variables in Tree
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